Inside information unaudited update on the 2026 third quarter
Filed with HKEX · Stock code 6618 · · 3 pages · English
Summary by 6ix AI
The company reported significant growth in its pharmaceutical partnerships and expanded its delivery services across numerous cities. Additionally, JD Health highlighted advancements in AI technology for healthcare consultations and management during this period. The filing includes preliminary financial figures, indicating changes in revenue and profit compared to the previous year, though these figures are unaudited and subject to adjustment.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
JD Health International, Inc. on 6ix
Earlier from JD Health International
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Chinese Biopharma Stocks Rally as Investors Favor Healthcare Over AI
- JD Health's Revenue Growth Likely Slowed in First Quarter — Market Talk
- CF Pharmtech Announces Strategic Cooperation With JD Health
Later from JD Health International
All JD Health International news releasesFollow JD Health International into a list and get an email when it puts out news.
Follow JD Health International